Qianhui Shang | Cancer Genetics | Best Researcher Award

Dr. Qianhui Shang | Cancer Genetics | Best Researcher Award

Sichuan University | China

Author Profile

Scopus

Orcid ID

🌟 Biography of Qianhui Shang, PhD 🌟

📚 EARLY ACADEMIC PURSUITS

Dr. Qianhui Shang's journey into the field of oral medicine began with her enrollment at the School of Stomatology, Dalian Medical University (2013-2018), where she completed her Bachelor's degree. Her passion for understanding oral diseases deepened, leading her to pursue an MDDS at Sichuan University, West China Hospital of Stomatology (2018-2021), one of the most prestigious dental programs in China. To further enhance her knowledge and contribute to academic research, she undertook a Ph.D. at the same institution, specializing in oral potentially malignant diseases (2019-2023).

👩‍⚕️ PROFESSIONAL ENDEAVORS

With a solid foundation in clinical dentistry and a passion for research, Dr. Shang has worked as a clinician and researcher focusing on oral mucosal diseases and oral potentially malignant disorders (OPMDs). Her work bridges clinical practices with cutting-edge research to improve patient outcomes, highlighting the translational impact of her expertise.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Dr. Shang has contributed extensively to the understanding of:

  1. Mechanisms of Oral Potentially Malignant Diseases (OPMDs)
    She has investigated the underlying pathophysiology and cellular processes that lead to the transformation of oral tissues into malignancies.
  2. Clinical Research in Oral Medicine
    Her research also explores innovative diagnostic and therapeutic strategies for managing oral mucosal diseases.

Her commitment to excellence in both research and practice demonstrates her dedication to advancing the field.

🌍 IMPACT AND INFLUENCE

Dr. Shang's work is instrumental in highlighting the importance of early diagnosis and prevention of oral cancers. Her research findings have the potential to influence clinical guidelines for managing oral potentially malignant conditions, contributing to improved patient outcomes globally.

📖 ACADEMIC CITATIONS

Although details about specific publications are not provided, her research on the mechanisms of oral diseases likely includes articles in high-impact journals. Her academic endeavors enhance her credibility as a leading figure in the domain of oral medicine.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Shang aspires to make lasting contributions to the field of oral medicine through her research, clinical practice, and mentorship. Her future vision involves:

  • Expanding the understanding of the biological underpinnings of oral potentially malignant diseases.
  • Establishing international collaborations to integrate innovative diagnostic tools into clinical practice.
  • Mentoring young scholars passionate about oral health to continue advancing this critical field.

✨ ABOUT DR. QIANHUI SHANG

  • Uygur origin, Xinjiang province.
  • Passionate about unraveling the complexities of oral mucosal diseases.
  • Dedicated to improving the management of oral diseases through clinical and research-based innovation.

📑NOTABLE PUBLICATIONS 

"Hydroxychloroquine is effective in oral lichen planus: A multicenter, randomized, controlled trial

  • Authors: Xie, Y. , Xu, H. , Li, C. , Zhou, Y. , Chen, Q. Oral
  • Journal: Diseases
  • Year: 2024

"Humoral immune disorders affect clinical outcomes of oral lichen planus

  • Authors: Qing, M. , Yang, D. , Shang, Q. , Xu, H. , Chen, Q.
  • Journal: Oral Diseases
  • Year: 2024

"The clinical implication and translational research of OSCC differentiation

  • Authors: Shang, Q. , Jiang, Y. , Wan, Z. , Chen, Q. , Xu, H.
  • Journal: British Journal of Cancer
  • Year: 2024

"Periodontitis and the risk of all-cause and cause-specific mortality among US adults with diabetes: A population-based cohort study

  • Authors: Li, W. , Peng, J. , Shang, Q. , Zhao, H. , Xu, H.
  • Journal: Journal of Clinical Periodontology
  • Year: 2024

"Angelicin inhibits cell growth and promotes apoptosis in oral squamous cell carcinoma by negatively regulating DUSP6/cMYC signaling pathway

  • Authors: Liu, N. , Li, C. , Shang, Q. , Xie, L. , Chen, Q.
  • Journal: Experimental Cell Research
  • Year: 2023

Yulian Ding | Molecular Basis of Genetic Disease | Best Researcher Award

Dr. Yulian Ding | Molecular Basis of Genetic Disease | Best Researcher Award

Shenzhen Institute of Advanced Technology | China

Author Profile

Scopus

Orcid ID

Google Scholar

🧬 YULIAN DING, PH.D. – PIONEER IN BIOMEDICAL ENGINEERING AND MACHINE LEARNING

EARLY ACADEMIC PURSUITS🎓

Yulian Ding embarked on her academic journey with a Bachelor of Science in Computer Science from Luoyang Normal University (2010-2014). Her passion for data science and bioinformatics was further solidified during her Master's degree in Computer Science at Shaanxi Normal University (2014-2017), where she focused on dynamic protein complex identification and essential protein identification through swarm intelligence optimization. Her research, under the guidance of Dr. Xiujuan Lei, shaped her understanding of computational biology and bioinformatics. In 2018, Yulian took her academic prowess to the next level by pursuing a Ph.D. in Biomedical Engineering at the University of Saskatchewan (2018-2022). Under the supervision of Dr. Fang-Xiang Wu, she developed advanced machine learning models to predict biomolecule-disease associations, working with miRNAs, lncRNAs, and circRNA.

PROFESSIONAL ENDEAVORS🧑‍🔬

Upon completing her Ph.D., Yulian Ding transitioned into various research roles that leveraged her expertise in both machine learning and biomedical engineering. From March 2022 to February 2023, she served as an Assistant Researcher at the Center for High Performance Computing, Shenzhen Institute of Advanced Technology, under the prestigious Chinese Academy of Sciences. Her work there focused on drug design and disease biomarker identification using machine learning techniques, contributing to major advancements in protein-ligand interaction prediction. Concurrently, Yulian completed a Postdoctoral Fellowship at the University of Saskatchewan’s College of Medicine and Division of Biomedical Engineering. She specialized in bio-data analytics, working on clinical data, particularly in identifying cirRNA biomarkers for cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR BASIS OF GENETIC DISEASE🔬

Yulian Ding’s research focuses on biomedical informatics, particularly at the intersection of machine learning and biomolecular interaction. Her key contributions lie in:

  • Developing novel machine learning models for predicting disease-associated biomolecules, including miRNAs, lncRNAs, and circRNA.
  • Drug design and disease biomarker discovery, particularly through the integration of machine learning in protein-ligand interactions.
  • Enhancing the understanding of bio-data analytics in oncology, utilizing vast datasets to identify crucial molecular targets for treatment.

IMPACT AND INFLUENCE🌍

Ding's work has had significant implications in precision medicine, especially in the early detection of diseases through biomarker identification. Her research on biomolecule-disease associations and the use of machine learning for drug discovery has positioned her as a rising leader in the biomedical engineering field. Her collaboration with leading scientists and institutions, including her postdoctoral work, has influenced both academic research and practical applications in biotechnology.

ACADEMIC CITES📚

Yulian Ding has been recognized for her academic excellence through numerous prestigious awards:

  • Dr. Victor A. Pollak and Mirka B. Pollak Scholarship (2021, University of Saskatchewan)
  • Russell (Russ) William Haid Memorial Award (2020, University of Saskatchewan)
  • China’s National Scholarship for Graduate Students (2017)
  • China’s National Second Prize of Lanqiao Cup Software Design Competition (2014)
  • ACM Programming Competition Silver Medal (2014)

Her work has been published in leading academic journals and recognized by international peers in the fields of bioinformatics and computational biology. As a journal reviewer for notable journals like Neurocomputing, Knowledge-Based Systems, and PLOS Computational Biology, she has contributed to shaping future research trends.

LEGACY AND FUTURE CONTRIBUTIONS🔮

Yulian Ding's legacy is deeply intertwined with her pioneering work in biomedical engineering. By harnessing the power of machine learning, she has opened new avenues for disease diagnosis and drug development. Her future endeavors are poised to push the boundaries of biomedical innovation, with a continued focus on applying computational intelligence to solve biomedical challenges. Through ongoing research and collaboration, Yulian will undoubtedly remain at the forefront of biomedical science, contributing to innovations that bridge the gap between computation and medicine.

 FINAL THOUGHTS🏅

Yulian Ding's academic journey, professional achievements, and innovative research establish her as a significant figure in biomedical engineering. Her work continues to make impactful contributions to precision medicine and biomedical informatics, shaping the future of healthcare through cutting-edge machine learning applications.

NOTABLE PUBLICATIONS📑

"MRDPDA: A multi-Laplacian regularized deepFM model for predicting piRNA-disease associations" 

  • Authors: Liu, Y. , Zhang, F. , Ding, Y. , Li, J. , Wu, F.-X.
  • Journal: Cellular and Molecular Medicine
  • Year: 2024

"P4PC: A Portal for Bioinformatics Resources of piRNAs and circRNAs" 

  • Authors: Liu, Y., Li, R., Ding, Y., Hei, X., Wu, F.-X.
  • Journal: Bioinformatics
  • Year: 2024

"Negative sample selection for miRNA-disease association prediction models" 

  • Authors: Ding, Y. , Wang, F. , Zhang, Y. , Wu, F.-X.
  • Journal: Machine Learning Methods for Multi-Omics Data Integration
  • Year: 2023

"Biomarker Identification via a Factorization Machine-Based Neural Network With Binary Pairwise Encoding" 

  • Authors: Ding, Y. , Lei, X. , Liao, B. , Wu, F.-X
  • Journal: IEEE/ACM Transactions on Computational Biology and Bioinformatics
  • Year: 2023

"MLRDFM: a multi-view Laplacian regularized DeepFM model for predicting miRNA-disease associations" 

  • Authors: Ding, Y. , Lei, X. , Liao, B. , Wu, F.-X
  • Journal: Briefings in Bioinformatics
  • Year: 2022

Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Dr. Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Chungna National University | South Korea

Author Profile 

Scopus

Google Scholar

BIOGRAPHY OF SANG YEON CHO 🌟

EARLY ACADEMIC PURSUITS 🎓

Sang Yeon Cho embarked on his academic journey at Chungnam National University, where he earned his Bachelor's degree in Biochemistry in 2012. He further pursued an M.S. in Medicine, obtaining his MD degree in 2021. Currently, he is completing his Ph.D. in New Drug Discovery and Development, expected to graduate in February 2025. His strong foundation in the sciences has equipped him with the skills necessary for innovative research in the medical field.

PROFESSIONAL ENDEAVORS 🏥

Currently, Dr. Cho serves as the Vice Director of the Metro Neurosurgery Clinic in Daejeon, South Korea, since October 2022. Prior to this role, he was the Vice Director of Hurisarang Hospital from March 2021 to September 2022. His leadership positions reflect his commitment to advancing medical practice and enhancing patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR CANCER BIOLOGY 🔬

As the Director of ChoLab since 2018, Dr. Cho has focused on cancer genomics and new drug discovery. His research has investigated the molecular mechanisms underlying cancer, emphasizing drug resistance and therapeutic targets. He has actively contributed to several labs, including the Neuroglia Lab and the Nano Primo Research Center, showcasing his multidisciplinary approach to tackling complex medical challenges.

IMPACT AND INFLUENCE 🌍

Dr. Cho's work has significantly influenced the field of medical genetics and cancer research. His publications in high-impact journals highlight the clinical significance of his findings, making substantial contributions to understanding cancer prognosis and treatment. Through his research, he aims to bridge the gap between laboratory discoveries and clinical applications, improving patient outcomes.

ACADEMIC CITATIONS 📚

His research output includes numerous peer-reviewed articles in respected journals such as BMC Medical Genomics, Scientific Reports, and BMC Cancer, where he explores topics like drug resistance, immunotherapy biomarkers, and cancer prognosis. His findings have garnered attention and citations within the academic community, underscoring the relevance and quality of his work.

LEGACY 🏆

Dr. Cho's dedication to advancing cancer research and patient care has already left a mark on the field. His innovative approach, exemplified by multiple patents related to AI in healthcare and cancer diagnostics, positions him as a forward-thinking researcher poised to shape future developments in medical science.

FUTURE CONTRIBUTIONS 🔮

Looking ahead, Dr. Cho aims to continue his research in cancer treatment and drug discovery, integrating cutting-edge technologies like artificial intelligence to enhance therapeutic strategies. With his expected Ph.D. completion in 2025, he is set to further expand his contributions to the field and inspire the next generation of medical researchers.

NOTABLE PUBLICATIONS 📑

"A method for the observation of the primo vascular system in the thoracic duct of a rat" 

  • Authors: Kim, S., Jung, S.J., Cho, S.Y., Soh, K.-S., Kim, S.
  • Journal: Evidence-based Complementary and Alternative Medicine
  • Year: 2013

"Protocol for the Observation of the Primo Vascular System in the Lymph Vessels of Rabbits" 

  • Authors: Jung, S.J., Cho, S.Y., Bae, K.-H., ... Song, Y.-K., Soh, K.-S.
  • Journal:  Journal of Acupuncture and Meridian Studies
  • Year: 2012

Xiang Gui Yang | Clinical Microbiology | Best Researcher Award

Xiang Gui Yang | Clinical Microbiology | Best Researcher Award

The First Affiliated hospital of Chengdu Medical College | China

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Yang Xianggui embarked on his academic journey at Harbin Medical University, where he earned a Bachelor's degree in Medical Laboratory Science. He further advanced his education at Chongqing Medical University, obtaining a Master's degree in Clinical Laboratory Diagnostics from the School of Laboratory Medicine.

PROFESSIONAL ENDEAVORS

Since July 2015, Yang Xianggui has been serving as the Deputy Chief Laboratory Physician at the First Affiliated Hospital of Chengdu Medical College. His primary focus is on research into bacterial resistance mechanisms and virulence, positioning him as a significant contributor to this critical field of medical research.

CONTRIBUTIONS AND RESEARCH FOCUS ON CLINICAL MICROBIOLOGY

Dr. Yang's research endeavors have been substantial and varied, including:

  • CRISPR/Cas9 Technology: Utilizing CRISPR/Cas9 to knock out the ftsZ gene in bacteria to study the molecular regulatory mechanism of the key enzyme MpI in the peptidoglycan cycle.
  • Gene Knockout Studies: Investigating the regulatory mechanism of acute-chronic infection transformation based on the nagZ gene knockout in Enterobacter cloacae.
  • MicroRNA Research: Exploring the application of miR-135 in detecting early-onset chronic kidney disease.
  • Enzyme and Protein Studies: Examining the correlation between Klebsiella pneumoniae KPC-2 enzyme and OmpK36, and studying the molecular regulatory mechanism of AmpC beta-lactamase, a key enzyme in the peptidoglycan cycle.

IMPACT AND INFLUENCE

Dr. Yang has been the principal investigator on several high-impact research projects funded by notable organizations:

  1. National Natural Science Youth Foundation Project: CRISPR/Cas9 technology study on ftsZ gene knockout.
  2. Sichuan Provincial Natural Science Foundation General Project: Regulatory mechanism study on acute-chronic infection transformation.
  3. Sichuan Provincial Department of Education Fund: Research on miR-135's application in early-onset chronic kidney disease detection.
  4. Chengdu Medical University Fund: Correlation study between Klebsiella pneumoniae KPC-2 enzyme and OmpK36.
  5. Special Fund of the First Affiliated Hospital of Chengdu Medical College: Study on the molecular regulatory mechanism of AmpC beta-lactamase.

ACADEMIC CITES

Dr. Yang has published nine SCI papers as the first author or corresponding author, showcasing his contributions to the scientific community. His work is recognized and cited by peers, reflecting his influence and expertise in bacterial resistance mechanisms and clinical laboratory diagnostics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yang's ongoing research projects and completed studies contribute significantly to the understanding of bacterial resistance and virulence. His legacy is built on his dedication to advancing laboratory medicine through innovative research and collaborative efforts. Future contributions are anticipated in the areas of infection control, molecular diagnostics, and bacterial resistance management, further enhancing his impact on medical science and patient care.

IMPORTANT TOPICS

  1. BACTERIAL RESISTANCE MECHANISMS: Exploring how bacteria develop resistance to antibiotics and identifying potential targets for new treatments.
  2. VIRULENCE FACTORS: Investigating the components that make bacteria pathogenic and how they can be neutralized.
  3. MOLECULAR REGULATORY MECHANISMS: Understanding the intricate molecular pathways that govern bacterial behavior and resistance.
  4. GENE KNOCKOUT TECHNOLOGIES: Utilizing advanced gene-editing tools like CRISPR/Cas9 to study bacterial genetics and physiology.
  5. CLINICAL APPLICATIONS: Translating research findings into practical applications in clinical diagnostics and treatment strategies.

NOTABLE PUBLICATIONS

PCT, IL-6, and IL-10 facilitate early diagnosis and pathogen classifications in bloodstream infection 2023(4)

Resistance of Klebsiella pneumoniae to Phage hvKpP3 Due to High-Molecular Weight Lipopolysaccharide Synthesis Failure 2023(3)

Application of Single-Cell Genomics in Cardiovascular Research 2023(2)

Cefazolin and imipenem enhance AmpC expression and resistance in NagZ-dependent manner in Enterobacter cloacae complex 2023(3)

Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression 2021(33)

Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Dr. Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Gregorio Maranon University Hospital | Spain

Author Profile

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Since 2017, I have been dedicated to advancing the field of pharmacogenetics, beginning as a research assistant and progressing through to postdoctoral researcher at the Pharmacogenetics Laboratory of the Gregorio Marañón General University Hospital. My journey started with foundational research roles and evolved into leadership positions within various pharmacogenomic studies.

PROFESSIONAL ENDEAVORS

Starting as a research assistant, I gradually transitioned to roles as a predoctoral and postdoctoral researcher, accumulating invaluable experience and expertise in pharmacogenetics. My work has been primarily focused on pharmacogenomic studies in diverse medical areas such as colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases.

CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOGENMICS AND PERSONALIZED MEDICINE

Throughout my career, I have actively contributed to 21 publications in pharmacogenomics, with a particular emphasis on colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases. Of these publications, I served as the first author for 14, showcasing my significant contributions to the field. Notably, my doctoral thesis in 2020 centered on intestinal inflammatory disease, underscoring my commitment to advancing knowledge in this area.

IMPACT AND INFLUENCE

My contributions have not gone unnoticed, as evidenced by receiving the AEFA (Spanish Clinical Laboratory Association) award for quality and innovation in 2019. Additionally, my research has been recognized through presentations at 20 national and international conferences, including 5 oral communications. I have been honored with the best oral communication award at three conferences, highlighting the impact of my work.

ACADEMIC CITES

My research has contributed to the academic discourse, with citations in various publications, further validating the significance and influence of my work in pharmacogenetics awards and related fields.

LEGACY AND FUTURE CONTRIBUTIONS

As an active member of the Spanish Society of Pharmacogenetics awards and the Spanish Association of Human Genetics, I continue to contribute to the advancement and dissemination of knowledge in these critical areas of public health. My ongoing commitment to research and collaboration ensures that my contributions will continue to shape the future of pharmacogenetics.

NOTABLE PUBLICATIONS

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children 2023(3)

Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease 2023(7)

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort 2023(7)

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain 2022(5)

Pharmacogenetics to avoid adverse reactions in cardiology: Ready for implementation? 2021(4)